reports
- Louis Boujard
- CFA
- Philippe Ourpatian
BMW BAYERISCHE MOTOREN WERKE AG
UBSN UBS GROUP AG
ALO ALSTOM SA
ELE ENDESA S.A.
VER VERBUND AG CLASS A
BA. BAE SYSTEMS PLC
BC8 BECHTLE AG
FDR FLUIDRA S.A.
EDW EDP RENOVAVEIS SA
AMS AMADEUS IT GROUP SA CLASS A
PRY PRYSMIAN S.P.A.
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ARGX ARGEN-X SE
KBX KNORR-BREMSE AG
NEXI NEXI S.P.A.
ENR SIEMENS ENERGY AG
ARM ARM HOLDINGS PLC
- Louis Boujard
- CFA
- Philippe Ourpatian
BMW BAYERISCHE MOTOREN WERKE AG
UBSN UBS GROUP AG
ALO ALSTOM SA
ELE ENDESA S.A.
VER VERBUND AG CLASS A
BA. BAE SYSTEMS PLC
BC8 BECHTLE AG
FDR FLUIDRA S.A.
EDW EDP RENOVAVEIS SA
AMS AMADEUS IT GROUP SA CLASS A
PRY PRYSMIAN S.P.A.
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ARGX ARGEN-X SE
KBX KNORR-BREMSE AG
NEXI NEXI S.P.A.
ENR SIEMENS ENERGY AG
ARM ARM HOLDINGS PLC
- Damien Choplain
- Martial Descoutures
Argenx : Product ramp-up continues
>Q1 in line on sales, below on EBIT - Q1 sales grew by 83% y-o-y and 6% q-o-q to $ 398m (US $ 347m, Japan $ 18m and EMEA $ 31m), reflecting the strong medical need in myasthenia gravis, the quality of products (i.e. Vyvgart and Vyvgart Hytrulo), as well as the excellent execution of the commercial rollout. The product should remain on this growth trajectory to achieve peak sales estimated at $ 11bn (vs the consensus at $ 11bn) in 2035, driven by the recent launch of ...
- Hilde Van Boxstael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
argenx FIRST LOOK: 1Q24 results on track, all eyes set on CIDP
This morning argenx reported its 1Q24 update, highlighting $ 398m sales and its pipeline progress. Mgmt is fully focused on expanding its commercial footprint into CIDP (PDUFA: June 21). Meanwhile, AAV was scrapped from the pipeline and systemic sclerosis (SSC) added. We maintain our € 435 TP and Buy rating.
- Damien Choplain
- Martial Descoutures
Argenx : La montée en puissance des produits se poursuit
>T1 en ligne sur les ventes, en dessous sur l’EBIT - Les ventes T1 progressent de 83% y-o-y et de 6% q-o-q pour atteindre 398 M$ (US 347 M$, Japon 18 M$ et EMEA 31 M$), reflétant le fort besoin médical dans la Myasthénie Gravis, la qualité des produits (i.e. Vyvgart et Vyvgart Hytrulo), ainsi que l’excellente exécution du déploiement commercial. Le produit devrait rester sur cette trajectoire de croissance pour atteindre un peak sales estimé à 11 Md$ (vs css 11 Md$) ...
argenx Reports First Quarter 2024 Financial Results and Provides Busin...
argenx Reports First Quarter 2024 Financial Results and Provides Business Update $398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second quarter 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 9, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its fi...
- David Seynnaeve
- PhD
argenx - Q1 beat on CSS
• Argenx published its Q1 update in which VYVGARD revenues slightly beat CSS by 2%• Two key news items: 1/ filing for the pre-filled syringe syringe for gMG and CIDP to be submitted in Q2 24 and 2/ decision to discontinue the planned development of efgartigimod in ANCA-associated vasculitis (AAV) following risk assessment of all ongoing studies based on learnings from ADDRESS and ADVANCE SC studies. CIDP PDUFA target action date of June 21 reiterated• Cash position stood at USD 3.1bn end of Marc...
argenx announces results of Annual General Meeting of Shareholders
argenx announces results of Annual General Meeting of Shareholders May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held today. All items on the agenda received a majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). As part of the approved resolutions: The Company's annual report and annual accounts for the financial year ending...
argenx to Present at BofA Securities 2024 Health Care Conference
argenx to Present at BofA Securities 2024 Health Care Conference May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 10:00 AM PT in Las Vegas, NV. A live webcast of the fireside chat may be accessed on the Investors section of the argenx website at . A replay of the webcast will be availabl...
Nyrstar NV – Update with regards to the proceedings before the Supreme...
Nyrstar NV – Update with regards to the proceedings before the Supreme Court Regulated Information Nyrstar NV – Update with regards to the proceedings before the Supreme Court 2 May 2024 at 17:30 CEST The Supreme Court rejects the appeal against the judgment of the Antwerp Court of Appeals dated 17 November 2022 Today, Nyrstar NV (the “Company”) provides an update with regards to the Supreme Court petition filed by a group of shareholders of the Company against the judgment of the Antwerp Court of Appeals dated 17 November 2022. In that judgment, the Antwerp Court of Appeals...
Nyrstar NV – Update met betrekking tot de procedure voor het Hof van C...
Nyrstar NV – Update met betrekking tot de procedure voor het Hof van Cassatie Gereglementeerde Informatie Nyrstar NV – Update met betrekking tot de procedure voor het Hof van Cassatie 2 mei 2024 om 17.30 CEST Het Hof van Cassatie verwerpt de voorziening tegen het arrest van het Hof van Beroep te Antwerpen van 17 november 2022 Nyrstar NV (de “Vennootschap”) geeft vandaag een update met betrekking tot de cassatievoorziening die een groep aandeelhouders van de Vennootschap heeft ingesteld tegen het arrest van het Hof van Beroep te Antwerpen van 17 november 2022. In dat arrest ...
argenx to Report First Quarter 2024 Financial Results and Business Upd...
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at . A replay of the ...
Nyrstar NV 2023 Full Year Results
Nyrstar NV 2023 Full Year Results Regulated Information Nyrstar NV 2023 Full Year Results 19 April 2024 at 07:00 CEST Nyrstar NV ("Nyrstar" or the “Company”) is today announcing the publication of its financial statements for the twelve months ended 31 December 2023 (“Full Year Results 2023”). The Full Year Results 2023 have been prepared on a discontinuity basis as a result of the decision of the extraordinary shareholders’ meeting of 9 December 2019 to reject the continuation of the Company’s activities. The Company has received from its auditor, and is publishing toda...
Nyrstar NV Jaarresultaten 2023
Nyrstar NV Jaarresultaten 2023 Gereglementeerde Informatie Nyrstar NV Jaarresultaten 2023 19 april 2024 om 07.00 CEST Nyrstar NV ("Nyrstar" of de “Vennootschap”) kondigt vandaag de publicatie van haar jaarrekening aan voor de twaalf maanden afgesloten op 31 december 2023 (“Jaarresultaten 2023”). De Jaarresultaten 2023 werden opgesteld op basis van discontinuïteit als gevolg van de beslissing van de buitengewone algemene vergadering van 9 december 2019 om de voortzetting van de activiteiten van de Vennootschap te verwerpen. De Vennootschap heeft van haar commissaris een co...
- Guy Sips
- Kristof Samoy
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
argenx FIRST LOOK: Additional CIDP data at AAN
argenx announced additional detail on its Phase 3 ADHERE data with Vyvgart Hytrulo, showcasing its speed of onset and depth of response. We believe that Vyvgart Hytrulo is well positioned vs. the approved standard-of-care IVIg/SCIg across patient types, and look forward to the FDA decision (PDUFA: June 21, 2024). € 435 TP and Buy rating reiterated.
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive ...
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment April 16, 2024 – 7:00am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, ...
- David Seynnaeve
- PhD
argenx - New CIDP & gMG data further underlines VYVGART (Hytrulo)'s va...
• ARGX shared additional results from the ADHERE (open-label) study and real-world data from gMG patients at the AAN Annual Meeting. • Data indicates rapid, deep, and clinically meaningful/sustained improvements in CIDP & with ability to reduce steroid burden (gMG). • We expect a positive outcome of the decision on regulatory approval for CDP by June 21 (85% LoA, +4% impact on TP) and currently project low double-digit million in sales this year. This might seem rather conservative (vs. gMG init...
- Damien Choplain
- Martial Descoutures
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.